Athena Athena

X
[{"orgOrder":0,"company":"Halia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Halia Therapeutics Presented Data on Targeting the NLRP3 Inflammasome for the Treatment of Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery"},{"orgOrder":0,"company":"Halia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Halia Therapeutics Announces First Participant Dosed in Phase 1 Clinical Study of HT-6184, a Novel NEK7\/NLRP3 Inhibitor","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Halia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Halia Therapeutics Presents at 4th Inflammasome Therapeutics Summit","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Halia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Halia Therapeutics Announces Completion of Enrollment for Phase I Clinical Trial of HT-6184","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Halia Therapeutics","sponsor":"Halia Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Halia Therapeutics Announces Collaboration with Canary Speech to Leverage its Cutting Edge AI-Driven Speech Technology to Advance the Clinical Development of Novel Therapeutics Targeting Neuroinflammation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by Halia Therapeutics

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The collaboration leverages Canary Speech's AI vocal biomarker platform which utilizes advanced AI algorithms to revolutionize the way Alzheimer's disease can be monitored and treated by integrating these insights to enhance the development and efficacy of its HT-4253 drug.

            Lead Product(s): HT-4253

            Therapeutic Area: Neurology Product Name: HT-4253

            Highest Development Status: Preclinical Product Type: Small molecule

            Recipient: Canary Speech

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration February 06, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            HT-6184 is the first drug candidate to target the protein NEK7 through an allosteric mechanism to inhibit NLRP3 inflammasome activity and it promotes the disassembly of the inflammasome once activated.

            Lead Product(s): HT-6184

            Therapeutic Area: Neurology Product Name: HT-6184

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 07, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            HT-6184, is the first to target NEK7 through an allosteric mechanism. HT-6184 prevents the interaction of NEK7 with NLRP3, which blocks the formation of the NLRP3 inflammasome complex, an important driver of chronic inflammation.

            Lead Product(s): HT-6184

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: HT-6184

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 01, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            HT-6184, novel small molecule inhibitor of NEK7 and NLRP3 pathway, is lead molecule from Halia's structure-based drug design strategy, which has produced pipeline of novel drug candidates targeting essential mediators of inflammation with potential to treat number of disease.

            Lead Product(s): HT-6184

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: HT-6184

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 15, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            NLRP3 acts as an essential downstream effector of signals that trigger inflammatory responses and has been implicated in driving the onset and progression of many chronic inflammatory diseases.

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 30, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY